1 Hematology Unit, Azienda USL-IRCCS Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy.
2 Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, via S. Pansini 80131 Naples, Italy.
3 Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, via G. Massarenti 9, 40138 Bologna, Italy.
4 Heamatology, Department of Precision and Translational Medicine, Sapienza University, piazzale A. Moro 5, 00185 Rome, Italy.
5 Hematology Division, AO S. Croce e Carle, via M. Coppino 26, 12100 Cuneo, Italy.
6 Hematology and Hematopoietic Stem Cell Transplantation Centre, Federico II University Hospital of Naples, via Pansini 80131 Naples, Italy.
7 Hemato-Oncology Unit, Istituto Oncologico della Svizzera Italiana (IOSI), via A. Gallino 12, 6500 Bellinzona, Switzerland.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Italy has been one of the first European countries hit by the COVID-19
pandemic, with many patients dying from severe respiratory issues,
especially frail subjects. Hematology patients are generally thought to
be at high risk of developing severe COVID-19-associated complications.
The aim of this work was to describe the infection control measures
adopted in Italian hematology settings to protect patients and
Materials and Methods
|Table 1. Geographic areas: univariate and multivariate analyses in and between subgroups.|
|Table 2. Type of patients cared: univariate and multivariate analyses in and between subgroups.|
|Table 3. List of responding centers|